Your browser doesn't support javascript.
Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study.
Pastor-Barriuso, Roberto; Pérez-Gómez, Beatriz; Hernán, Miguel A; Pérez-Olmeda, Mayte; Yotti, Raquel; Oteo-Iglesias, Jesús; Sanmartín, Jose L; León-Gómez, Inmaculada; Fernández-García, Aurora; Fernández-Navarro, Pablo; Cruz, Israel; Martín, Mariano; Delgado-Sanz, Concepción; Fernández de Larrea, Nerea; León Paniagua, Jose; Muñoz-Montalvo, Juan F; Blanco, Faustino; Larrauri, Amparo; Pollán, Marina.
  • Pastor-Barriuso R; National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain.
  • Pérez-Gómez B; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Hernán MA; Joint first authors.
  • Pérez-Olmeda M; National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain.
  • Yotti R; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Oteo-Iglesias J; Joint first authors.
  • Sanmartín JL; Departments of Epidemiology and Biostatistics, Harvard TH Chan School of Public Health; Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • León-Gómez I; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Fernández-García A; Institute of Health Carlos III, Madrid, Spain.
  • Fernández-Navarro P; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Cruz I; Spanish Network for Research in Infectious Diseases (REIPI), Institute of Health Carlos III, Madrid, Spain.
  • Martín M; Ministry of Health, Madrid, Spain.
  • Delgado-Sanz C; National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain.
  • Fernández de Larrea N; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • León Paniagua J; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Muñoz-Montalvo JF; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Blanco F; National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain.
  • Larrauri A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Pollán M; National School of Public Health, Institute of Health Carlos III, Madrid, Spain.
BMJ ; 371: m4509, 2020 11 27.
Article in English | MEDLINE | ID: covidwho-947819
ABSTRACT

OBJECTIVE:

To estimate the infection fatality risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on deaths with confirmed coronavirus disease 2019 (covid-19) and excess deaths from all causes.

DESIGN:

Nationwide seroepidemiological study.

SETTING:

First wave of covid-19 pandemic in Spain.

PARTICIPANTS:

Community dwelling individuals of all ages. MAIN OUTCOME

MEASURES:

The main outcome measure was overall, and age and sex specific, infection fatality risk for SARS-CoV-2 (the number of covid-19 deaths and excess deaths divided by the estimated number of SARS-CoV-2 infections) in the community dwelling Spanish population. Deaths with laboratory confirmed covid-19 were obtained from the National Epidemiological Surveillance Network (RENAVE) and excess all cause deaths from the Monitoring Mortality System (MoMo), up to 15 July 2020. SARS-CoV-2 infections in Spain were derived from the estimated seroprevalence by a chemiluminescent microparticle immunoassay for IgG antibodies in 61 098 participants in the ENE-COVID nationwide seroepidemiological survey between 27 April and 22 June 2020.

RESULTS:

The overall infection fatality risk was 0.8% (19 228 of 2.3 million infected individuals, 95% confidence interval 0.8% to 0.9%) for confirmed covid-19 deaths and 1.1% (24 778 of 2.3 million infected individuals, 1.0% to 1.2%) for excess deaths. The infection fatality risk was 1.1% (95% confidence interval 1.0% to 1.2%) to 1.4% (1.3% to 1.5%) in men and 0.6% (0.5% to 0.6%) to 0.8% (0.7% to 0.8%) in women. The infection fatality risk increased sharply after age 50, ranging from 11.6% (8.1% to 16.5%) to 16.4% (11.4% to 23.2%) in men aged 80 or more and from 4.6% (3.4% to 6.3%) to 6.5% (4.7% to 8.8%) in women aged 80 or more.

CONCLUSION:

The increase in SARS-CoV-2 infection fatality risk after age 50 appeared to be more noticeable in men than in women. Based on the results of this study, fatality from covid-19 was greater than that reported for other common respiratory diseases, such as seasonal influenza.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroepidemiologic Studies / COVID-19 Type of study: Observational study / Prognostic study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Europa Language: English Journal: BMJ Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Bmj.m4509

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroepidemiologic Studies / COVID-19 Type of study: Observational study / Prognostic study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Europa Language: English Journal: BMJ Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Bmj.m4509